Background: Women-specific factors exist that increases vulnerability to drug-related harms from injecting drug use including bloodborne viruses (BBV), but gender differences in BBV prevalence have not been systematically examined.
Introduction
Globally, an estimated 15.6 million people have injected drugs in the previous year, of whom 3.2 million (20%) are women. [1] Representation of women amongst people who inject drugs (PWID) varies greatly by region, with higher proportions observed in high income areas (e.g., Australasia: 33%; North America: 30%) and lower proportions in lower-income regions (e.g., South Asia: 3%; Middle East and North Africa: 4%). [1] Blood-borne viral infections (BBV), including HIV, hepatitis C virus (HCV) and hepatitis B virus (HBV) are highly prevalent among PWID. [1] Women who inject drugs may be at elevated risk of BBVs compared to men for a multitude of reasons. Although stigma, marginalization, and discrimination are commonly experienced by PWID regardless of gender, these experiences are particularly salient for women who inject drugs. [2] [3] [4] Women who inject drugs experience significant barriers in accessing healthcare, including harm reduction services such as needle and syringe programs, and drug treatment services, [2] [3] [4] and may also experience stigma and discrimination within drugusing networks. Women are more likely to inject in a social setting and be last in line when sharing equipment, [5] and more likely to be exposed to higher risk for sexual transmission of infections, through sex work and sexual violence from clients, intimate partners and law enforcement. [5, 6] There are mixed findings on the effect of gender on BBV risk. In a review on high HIV prevalence (>20%) PWID samples, women had an elevated risk of infection than men (odds ratio 1.18; 95% CI: 1.10, 1.26), [7] while a review of data from Central Asian countries reported no significant gender differences. [8] An analysis of HIV prevalence amongst PWID reported to UNAIDS identified significant variation in gender differences between countries. [9] HCV incidence appears to be higher among women who inject drugs compared to men, [10] although exposure to HCV is so common among PWID that prevalence may be equally high among men and women who have been injecting for many years. [11] An estimated 9% of PWID globally have acute or chronic HBV infection, [1] however, to our knowledge, there has been no systematic review and meta-analysis of gender Downloaded from https://academic.oup.com/jid/advance-article-abstract/doi/10.1093/infdis/jiz058/5307802 by guest on 07 February 2019 A c c e p t e d M a n u s c r i p t differences in HBV infection among PWID. It is also unknown whether an overall higher prevalence of BBV in the general population would reduce stigma and gender-minority specific risks associated with injecting drug use.
The aims of the present study were to estimate: 1) prevalence of HIV, HCV antibodies (anti-HCV) and Hepatitis B surface antigen (HBsAg) among PWID by gender and by country; 2) relative risks of HIV, anti-HCV and HBsAg in women compared to men who inject drugs by country; and 3) country-level indicators of health, development and inequality associated with gender differences in HIV, anti-HCV and HBsAg among PWID.
Methods

Data source
Data on BBV among people with recent (past year) injecting drug use were drawn from our multi-stage global systematic review on the prevalence of injecting drug use, and BBV among PWID [1] with a-priori protocols [12, 13] (Supplementary Material Appendix A-C for methods). In this article, we included a subset of 104 studies with adequate data on prevalence of BBVs by gender to conduct our meta-analysis, which were not analysed nor presented in previous reviews. Data were available for 38 (total sample size of N=146,136 PWID from 79 studies), 33 (N=90,746 from 53 studies), and 17 countries (N=30,087 from 15 studies) for gender differences in HIV, anti-HCV, and HBsAg, respectively (see Table 1 ).
<Table 1>
Country-level indicator variables
Country-level indicators of health, development and inequality examined included HIV, HCV and HBV prevalence in the general population [14] , country income level (low/middle or high), income inequality measured by the Gini coefficient [15] , the Gender Inequality Index [16] , and the Human Development Index (HDI) [17] . 
Data analysis
Random-effects meta-analyses were used to pool multiple estimates within each country based on heterogeneity (I²>75%). Country-level gender differences in BBV were estimated by pooling the relative risks (RR) of BBV among women versus men across studies within each country and used to calculate the weighted RR estimates at the regional and global levels, weighting by population sizes of PWID [1] . To allow for more robust prevalence levels, the RR were then applied to the overall (not sex specific) country, regional, and global prevalence of BBV published in the multi-stage global systematic review on IDU and BBV among PWID [1] to split the published estimates into separate prevalence for women and men. Due to the sparsity of data availability in some regions, sensitivity analyses were conducted borrowing strength from nearby countries within the same region for countries with limited data. Further details on the analysis methods are available in Appendix D.
To examine the associations of country-level indicator exposure variables with gender differences in BBV prevalence in PWID, we used generalized linear models to model the log RRs of women compared to men as the outcome, clustering by country. Country-level indicators that were prevalence variables were logit transformed using the formula ln (p / (1p)). We tested for non-linear associations by adding quadratic terms of exposure variables in the models, which were retained if the likelihood ratio tests reviewed a significantly better model after inclusion. Adjusted models included country-level BBV prevalence in the general population and region.
Results
Blood-borne viruses among PWID by gender
The degree of difference between men and women varied substantially by region and by blood-borne virus type (see Table 2 ). Globally, the prevalence of BBV in women and men who inject drugs were 19.1% (95% CI 7.9-30.4) and 17 .5% (7.2-27.8) for HIV, 48.9% (95% CI 33.8-64.0) and 55.7% (95% CI 38.5-72.8) for anti-HCV, and 7.8% (0-16.1) and 10.4% (0-21.6) for HBsAg, respectively. Global HIV prevalence was slightly higher in women than men Downloaded from https://academic.oup.com/jid/advance-article-abstract/doi/10.1093/infdis/jiz058/5307802 by guest on 07 February 2019 A c c e p t e d M a n u s c r i p t (RR=1.10, 95%CI 0.68-1.77), while prevalence of anti-HCV and HBsAg were lower in women (RR=0.88, 95% CI 0.71-1.09 and RR=0.75, 95%CI 0.36-1.56), all however not statistically significant. At the regional level ( Sensitivity analyses results were consistent, supporting that the regional estimates were robust based on the available data (see Appendix F). The sensitivity analyses demonstrated that when we replace country estimates that only have one study informing the estimates based on estimates from other countries within the same region, there is little change in the conclusions, however there are larger gaps in the results.
<Table 2>
At the country-level, risk ratios for eight countries (Nigeria, Tanzania, Mexico, India, Mauritius, Germany, Ukraine, and Spain) indicated higher HIV prevalence among women than men; two countries (Australia and Myanmar) indicated lower HIV prevalence amongst women; and 28 countries showed no significant gender differences. The risk of HIV for women was five-fold greater than men in Nigeria, and more than two-fold greater in Tanzania, India, and Mexico. For anti-HCV prevalence, six countries (Myanmar, Finland, Spain, Nepal, Tunisia and Turkey) demonstrated lower prevalence among women; two countries (India and Kyrgyzstan) had higher risk among women; and 25 countries no significant gender differences. Across all countries there was no significant difference in HBsAg prevalence by gender (see Appendix G for country-level prevalence and relative risk estimates). 
Country-level indicators associated with gender differences in BBV prevalence among PWIDs
Gender differences in HIV among PWID were positively associated with country-level HIV prevalence in the general population (see Figure 1 [available online] and Table 3a) , with an increasing slope at high population prevalence levels towards data from Sub-Saharan Africa. A U-shape quadratic trend was apparent between gender differences in HIV among PWID and country-level HBV prevalence turning at mid-levels of population-level HBV prevalence, which held after excluding the outlier data-point from Mexico with high gender differences but low HBV prevalence, and in the adjusted model. Lower levels of HDI and higher levels of income inequality were associated with higher risk of HIV among women who inject drugs, but these were not significant in the adjusted models.
<Figure 1> <Table 3>
Higher risks of anti-HCV in women were associated with lower country-level HBV prevalence, and higher HDI, although these were not significant in the adjusted models (see Figure 2Figure 2 [available online] and Table 3b ).
Lower Gini scores (indicating lower income inequality in the country) were associated with higher risk of anti-HCV among women, with a decreasing slope from countries with a Gini of 35 onwardsFigure 2.
<Figure 2>
Lower country-level HCV prevalence in the population were associated with higher risks of HBsAg among women who inject drugs compared with men who inject drugs (see Figure 3 [available online]). We found no other indicators significantly associated with gender difference in HBsAg. <Figure 3Figure 3> 
Discussion
This is the first systematic review and meta-analysis to examine gender differences in the prevalence of HIV, anti-HCV and HBsAg among PWID by country, region, and globally, and to investigate country-level characteristics associated with gender differences. Globally, there was no statistically significant difference in BBV by gender among people who had recently injected drugs. Gender differences in HIV among PWID were associated with higher country-level HIV prevalence, higher country-level HBV prevalence, lower human development index, and higher inequality. Gender differences in anti-HCV among PWID were associated with lower country-level HBV prevalence, higher human development index, lower inequality, and higher country income level, although the latter three were not statistically significant after controlling for country-level anti-HCV and region. Gender differences in HBsAg among PWID were only associated with lower country-level HCV prevalence.
There were considerable global variations in gender disparities on BBVs among PWID. Of the country-level indicators examined, none were consistently associated with gender disparities, although associations between indicators and specific BBV were observed. A hypothesis for the variations in gender differences in HIV prevalence by region is that elevated sexual risks may be more important than injecting risks in some settings. We were unable to test this hypothesis, as for HIV (which we had the highest number of studies available) there were only nine studies that reported the percentage of sample involved in sex work. More studies should be collecting information on sexual and injecting risk factors among PWID. Drawing on existing literature, among PWID, more women are involved with sex work.[18] Women who inject drugs involved in sex work may be more likely to experience injecting risk behaviours than other women who inject drugs.[19-21] However, studies do not consistently show higher HIV prevalence among this group compared to women who inject drugs but are not sex workers. [20, [22] [23] [24] [25] [26] Of countries with data, most did not showed a significant gender difference in HIV prevalence. We observed higher HIV among women in countries including Nigeria, Tanzania, India, and Mexico. A recent Global Drug Survey study highlighted several gender role-related factors that disadvantage women [28] , which is a potential explanation for our findings. Based on self-reported data in PWID, women had over four times higher odds to have been injected by an A c c e p t e d M a n u s c r i p t intimate partner. [28] Women were had lower access to sterile injecting equipment, and more likely to have shared injecting equipment. These findings support that women are more dependent on their partner for their drug use, consistent with the theme of women having less say in practicing safe sex and drug use [5, 28] In addition, due to stronger stigma against women who inject drugs, women often experience greater social isolation than men who inject drugs, which strengthens their dependency on their intimate partners. [29] [30] [31] [32] [33] [34] As with HIV, in most countries with the necessary data, no gender difference was apparent in HCV prevalence among PWID. Where a gender difference was apparent for anti-HCV, women who inject drugs generally had lower prevalence than their male counterparts. In contrast, a recent analysis of the International Collaboration of Incident HIV and HCV in Injecting Cohorts (InC3) found that women who inject drugs had significantly greater risk of HCV acquisition than men, HR=1.39 (95%CI=1.12-1.72). [36] HCV is endemic among PWID, with older cohorts or those with a longer injecting history having near-universal exposure to the virus. [37] It may be that in countries where women had lower HCV prevalence than men, the women were younger or more recent initiates to injecting than men in the same studies. As we could not examine sex differences stratified by age or duration of injecting drug use, it is not possible to assess this proposition. No clear evidence of a gender difference in HBsAg prevalence among PWID was identified, yet the paucity of data available on HBsAg must be heavily emphasised.
Our finding that HIV prevalence was similar among women compared to men who inject drugs globally are inconsistent with a previous meta-analysis, which did find a significant higher risk among women, although the effect size was modest. [7] However, our review differed in inclusion criteria, as the previous review only included data on high seroprevalence samples from 14 countries. [7] Consistent with that previous review, we also highlight the heterogeneity of findings between studies and locations. The previous meta-analysis examined whether national income, percentage of females in the study sample, and recruitment settings contributed to the heterogeneity, however revealed a null finding. In our study, we examined additional country-level indicators and found several measures that are associated with variations in gender differences in BBV. We observed greater risks of HIV in women who inject drugs in countries with higher income inequality and lower human development, which was not the case for anti-Downloaded from https://academic.oup.com/jid/advance-article-abstract/doi/10.1093/infdis/jiz058/5307802 by guest on 07 February 2019 A c c e p t e d M a n u s c r i p t HCV. We also found that more studies from low and middle-income countries reported higher risk of HIV among women who inject drugs compared to studies from high income countries, but this observation did not reach statistical significance. Looking at country-level prevalence of BBV in the general population, we found greater risks for women who inject drugs in countries with greater general population HIV and HBV prevalence. Both HIV and HBV can be sexually transmitted, and this finding lend additional support to sexual risk being a key factor in our observed gender disparities. The trend can be partly explained by studies from countries in Sub-Saharan Africa with high gender differences in HIV as well as high general population HIV and HBV prevalence. Country-level HBV was associated with gender differences in anti-HCV among PWID, while country-level HCV was associated with gender differences in HBsAg among PWID. Together, these observations support that our findings are likely to be partly driven by regional differences (data by region are available in Appendix E and online). Heterogeneity in data source and availability may also be partly responsible for our finding. There were more high-income countries with high HCV prevalence, which is different from the epidemiology of HIV. We had more data from countries in the East and South East Asia and Sub-Saharan Africa regions for HIV than for anti-HCV, therefore results are unlikely to be directly comparable. Our findings of indicators associated with gender differences in BBV is likely to differ by regions.
However, there were insufficient data to conduct analysis stratified by region.
Social differences between women and men who inject drugs may also affect their risk of BBV. Women who inject drugs are less likely than men who inject drugs to access and be retained in services such as methadone and buprenorphine-based treatment when women are the minority. [38] Under-representation of women who inject drugs in treatment is particularly an issue in developing countries. This is supported by a recent study from Tanzania, which found that non-enrolment in methadone maintenance treatment among women who use heroin was associated with intimate partner violence and experience of discrimination by healthcare provider. [39] Barriers for women who inject drugs to access drug treatment services often involve complex interactions of multiple women-specific social, structural, and psychological factors, such as stronger levels of stigma, violence, sex work, concealment of their injection risk, and fear of loss of custody of children. [38] Indeed, a previous review found better effectiveness and adherence of drug treatment for women in programs that involve women specific designs, such as child care, prenatal A c c e p t e d M a n u s c r i p t care, women-only programs, and workshops that address women-focused topics. [40] In addition, there are differences in demographics and drug-use characteristics of PWID by gender, which may have implications for BBV, and lends support to provide gender appropriate treatment options. [41] Our findings suggest that this is particularly important in low-and middle-income countries and those with higher income inequality. In addition, previous research has shown that decriminalisation of drug use improves HIV prevention and treatment [42] , which is a public health approach that can reduce stigmatization and drug-related harms in both men and women who inject drugs.
Limitations
Several caveats should be noted in the interpretation of these findings. Key amongst these is the scarcity of data.
Specifically, estimates of BBV prevalence were only available for one-third to one-fifth of countries where there was evidence of injecting drug use occurring (HIV: 52.4%; anti-HCV: 47.6%; HBsAg: 35.9%) and, of these, only one-fifth to one-third countries had estimates of prevalence separately for men and women (HIV 35.2%; anti-HCV: 33.7%;
HBsAg: 23.0%). Regions with the highest data coverage include Europe and Australasia, while regions with the lowest data coverage included Latin America and Caribbean and Pacific Islands. We ensured more representative estimates by applying the gender ratio (derived from the subset of studies with data by gender) to the prevalence of BBV reported for total sample (from all studies). Yet, lack of quantification of BBV prevalence in men and women separately persists, despite earlier work highlighting the paucity of data and calling for action to rectify this situation. [8] Future studies that employ methods involving targeted sampling of women who inject drugs will be important, especially in countries and regions with smaller proportions of women who inject drugs where women may be more marginalised. In addition, sexual minorities and transgender women, which we found no data for in this article, is another under-studied subpopulation who are at elevated levels of marginalization and HIV [27], hence future studies are needed to understand the potential social, structural, interpersonal and intrapersonal factors that may elevate risks in this group to achieve equity.
We were also limited by the sample sizes of included studies. There were several studies that met our minimal inclusion criteria for the total sample size, yet women were underrepresented in the sample, which we then had to A c c e p t e d M a n u s c r i p t exclude. To minimise biases of detecting no cases due to small sample sizes, we applied an additional criterion of excluding studies with zero cases detected. Studies of BBV prevalence and other harms among PWID may need to employ strategies to ensure adequate recruitment of both sexes, including involvement of PWID in developing and implementing research projects; respondent-driven sampling with women (and, for example, sexual and racial minority PWID) as seed participants; and/or sex-stratified sample size targets. [9, 43] Further, most studies which reported BBV prevalence by gender did not break the sample down into age groups. As a result, we were not able to adjust for, or examine the effects of age on gender differences in BBV among PWID. There were also insufficient data to examine demographic and behavioural characteristics hypothesised to be associated with BBV prevalence, such as commercial sex work. Future studies should examine the effectiveness of HIV interventions for reducing risks among women who inject drugs, especially in locations where we found high rates of HIV among PWID. Lastly, we cannot definitively say that country-level indicators adopted here accurately reflect the situation for PWID in that country; for example, a country with high levels of gender equality in the overall population may have low levels of gender equality among the PWID sub-population. Future studies with data on local factors among the PWID sub-populations would contribute to our understanding of where women who inject drugs might face greater stigmatization that may put them at greater vulnerability to adverse health outcomes.
Conclusion
Our review highlighted that there are country-level factors which indicate a gender difference in BBV among PWID.
We also highlighted the need to improve the quality and quantity of data on BBV in the PWID population, particularly in relation to sex-specific prevalence estimates, and especially in low and middle-income countries. Collecting nuanced data on risk exposures is also needed to clarify the extent to which injecting vs sexual risk behaviours influence BBV prevalence in women who inject drugs. Such data are critical to advocate for resources and interventions for women who inject drugs. BBV prevalence remains unacceptably high in PWID, highlighting the need for increased access to effective prevention interventions including needle and syringe programs and opioid agonist treatment, as well as treatment for PWID living with HIV and HCV to prevent further infections. Attention A c c e p t e d M a n u s c r i p t 
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